| Revenue Growth | H&H $188M (+8.1%), ANH $63M (+11.7%), Specialty $37M (+4.5%). |
|---|---|
| Mgmt Confidence | High; cited 29 consecutive quarters of year-over-year adjusted EBITDA growth. |
| Demand Visibility | Healthy demand across majority of businesses; positive long-term outlook for nutrients. |
| Margin Trends | Gross margin expanded 70 bps to 36.4% via favorable product mix. |
| Op. Leverage | Operating expenses rose to $43M from $41M due to higher compensation. |
| Pricing Power | Successfully passed through raw material inflation dollar-for-dollar to customers. |
| Vol vs Price | Growth driven by higher sales volumes and favorable product mix. |
| Segment Growth | ANH outperformed with 11.7% growth; H&H record sales of $188M. |
| New Clients | Exploring beauty industry partnerships; upcoming international sports team partnership announcement. |
| Capex & Debt | Reduced net borrowings by $28M; net leverage ratio at 0.2x. |
| Regulatory | EU anti-dumping duties helping; filed for anti-dumping duties in US. |
| Commentary | Strategic focus on science-backed branded ingredients like VitaCholine and K2VITAL. |
| New Launches | Next-generation encapsulated methionine launched October 1st; new encapsulated lysine driving growth. |
Growth
Consolidated revenue grew 8.6% to $291M; H&H up 8.1%, ANH up 11.7%, Specialty up 4.5%.
Outlook
Management expects Q4 to be sequentially lower due to seasonality but deliver healthy year-over-year growth.
Risks
Management pivoted on specific inventory reduction timelines, citing geopolitical risks and upcoming product launch safety stocks.
The company's earnings call, NASDAQ: BCPC, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Balchem Corp: key numbers
- Share price
- $171.48Close, Nov 16
- Market cap
- $5.45B
- Shares outstanding
- 31.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Chemicals & Allied ProductsSIC 2800
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Balchem Corp
All →Balchem Q3 2026 Results: Net Income $46.7M, Up 16.0% YoY
Balchem Corp reported net sales of $290.7 million for the third quarter of 2026, a 8.6% increase compared to the prior year, with net earnings rising to $46.7 million. For the nine months ended September 30, 2026, the company generated $156.5 million in cash from operations while significantly increasing inventory levels and continuing its common stock repurchase program.
- Key figure
- Net income $46.7M · +16.0% YoY
Balchem Financial Results
Balchem Corporation reported record third quarter 2026 financial results, with net sales increasing 8.6% year-over-year to $290.7 million. The company achieved growth across all three reporting segments and repurchased approximately $28 million of common stock during the quarter.
- Term
- Q3 2026
“Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”
Ted Harris, Chairman, President and CEO
“With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”
Ted Harris, Chairman, President and CEO